Intravitreal Aflibercept Outcomes in Patients with Persistent Macular Exudate Previously Treated with Bevacizumab andor Ranibizumab for Neovascular Age-Related Macular Degeneration

الملخص EN

Purpose.

To assess whether intravitreal aflibercept (2.0 mg) can effectively reduce persistent macular exudate and enhance visual acuity in ranibizumab (0.5 mg) and/or bevacizumab (1.25 mg) treatment resistant patients with neovascular age-related macular degeneration.

Methods.

This retrospective study included 47 treatment resistant eyes from 47 patients switched to intravitreal aflibercept injections after receiving a minimum of 3 injections with either ranibizumab or bevacizumab.

Snellen visual acuity and optical coherence tomography were assessed just prior to the first injection (baseline) and prior to the fourth injection (final).

Additionally, anatomical regions of persistent macular exudate were tracked to determine if these areas yielded varying responses to aflibercept.

Results.

At baseline, patients had received an average of 11.3 injections with any prior anti-VEGF drug (SD 5.96).

For whole group analysis, baseline and final central retinal thickness were 370.57 µm and 295.7 µm ( P ≤ .

001 ), respectively.

Baseline and final retinal fluid volumes were 4.81 mm3 and 4.37 mm3 ( P ≤ .

001 ), respectively.

Baseline and final logMAR were 0.56 and 0.53 ( P = 0.301 ), respectively.

Anatomic location of persistent exudate did not appreciably alter treatment outcome.

Conclusion.

Central retinal thickness and total retinal fluid volume were reduced in ranibizumab and/or bevacizumab treatment resistant patients following three aflibercept injections.

No appreciable change in visual acuity was noted.